secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001493152-25-006584
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics enters $3.3M ATM equity offering with H.C. Wainwright
------------------------------------------------------------------------

- Filed ATM offering agreement to sell up to $3,328,881 of common stock through H.C. Wainwright.
- Wainwright will receive a 3% cash commission on gross sales proceeds as agent.
- Offering terminates upon sale of all shares or earlier termination by either party.
- Amended employment agreements for CEO Huntsman and CFO Amman effective Jan 1, 2025 (previously reported).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315225006584/0001493152-25-006584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315225006584/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-006584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer